Search
for
Sort by
Research 781–810 of 1000+
- Antioxidants and Long Covid
- PLATELET RİCH PLASMA RESULTS IN THE TREATMENT OF FEMUR HEAD AVASCULAR NECROSIS
- The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
- The role of sleep in telogen effluvium and trichodynia: A commentary in the context of the current pandemic
- Hypothalamic-pituitary-adrenal axis, hair, and sebum: Stress-mediated dermatologic disasters of the pandemic era
- Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia
- Novel Synthetic Steroid Derivatives: Target Prediction and Biological Evaluation of Antiandrogenic Activity
- From bedside to bench: regulation of host factors in SARS-CoV-2 infection
- A systematic review on Drug Re-profiling/Re-Purposing
- Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
- The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
- Insights About a Pandemic: Clinical Approach
- Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
- Genomic Surveillance Reveals the Rapid Expansion of the XBB Lineage among Circulating SARS-CoV-2 Omicron Lineages in Southeastern Wisconsin, USA
- Anais do II Congresso Nacional Acadêmico de Dermatologia
- ANAIS DO I CONGRESSO MÉDICO DE FORMOSA - COMEF
- Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
- Kaleidoscope
- Coronavirus Infection and Cholesterol Metabolism
- The Advances of Broad-Spectrum and Hot Anti-Coronavirus Drugs
- Before & beyond the pain – Allostatic load, central sensitivity and their role in health and function
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Hair loss in women
- Bioactivity and In Silico Studies of Isoquinoline and Related Alkaloids as Promising Antiviral Agents: An Insight
- Male sex hormones, aging, and inflammation
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Current Development of Mesenchymal Stem Cell-Derived Extracellular Vesicles
- Systematic characterization of the barrier function of diverse ex vivo models of damaged human skin
- Impact of anticancer therapy on the quality of life of Sudanese patients with breast cancer at Khartoum oncology hospital